Loading
Liver Disease Diagnosis and Treatment / Gastrointestinal Motility and Disorders · Review
Obesity Surgery · August 11, 2026
Encouraging direction, but not yet definitive.
This meta-analysis of six small studies (n=220, follow-up 6–12 months) reports that endoscopic gastric remodeling reduces noninvasive fibrosis markers (NFS, HSI), liver enzymes, and improves weight loss and glycemic control. The evidence is based on surrogate endpoints and short-term data; durability and clinical hard outcomes remain unknown, and the authors themselves call for longer-term studies.
Systematic review and meta-analysis. Six studies comprising 220 patients with metabolic dysfunction-associated steatotic liver disease; mean age 45 years, 67.5% female, mean baseline BMI 38.9 kg/m²; follow-up 6–12 months.. Intervention: Endoscopic gastric remodeling (ESG, EGP, or POSE). n = 220.
NAFLD Fibrosis Score reduced by mean difference −0.65 (95% CI −0.89 to −0.42) Hepatic steatosis index decreased from 50.36 ± 3.00 to 42.66 ± 2.38 Alanine aminotransferase reduced by pooled 14.39 U/L; aspartate aminotransferase by 6.58 U/L
Outcomes are noninvasive fibrosis indices, not biopsy-proven fibrosis or clinical liver events (cirrhosis, hepatic decompensation, mortality).
These results suggest endoscopic gastric remodeling may improve hepatic fibrosis markers and metabolic parameters in MASLD over 6–12 months. However, clinicians should await longer-term studies and clinical (hard) outcome data before considering this a standard-of-care intervention, as the evidence currently rests on surrogate endpoints and short follow-up in small cohorts.
Systematic review of 6 small studies (220 patients, 6–12 month follow-up) showing improvements in fibrosis indices and metabolic markers, but short-term surrogate endpoints without hard liver outcomes or long-term durability data.
As stated by the source record.
Quoted from the source exactly as published.
These results suggest endoscopic gastric remodeling may improve hepatic fibrosis markers and metabolic parameters in MASLD over 6–12 months. However, clinicians should await longer-term studies and clinical (hard) outcome data before considering this a standard-of-care intervention, as the evidence currently rests on surrogate endpoints and short follow-up in small cohorts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver disease in the United States, is linked to obesity and insulin resistance. Endoscopic gastric remodeling (EGR) offers a safe and effective minimally invasive approach for MASLD. It is associated with improvements in noninvasive fibrosis test (NIT), liver enzymes, weight reduction, and metabolic parameters than bariatric surgery in the management of obesity. EGR includes three primary approaches: endoscopic sleeve gastroplasty (ESG), endoscopic gastric plication (EGP), and primary obesity surgery endoluminal (POSE). AIM: To evaluate the effects of EGR on MASLD-related liver outcomes and metabolic parameters. METHODS: A systematic search of multiple electronic databases, including conference proceedings, was conducted from database inception through November 2025 to identify studies reporting hepatic or metabolic outcomes following EGR. Weighted mean differences and pooled proportions were calculated using a fixed-effects model. Heterogeneity was assessed using Cochran's Q test. Primary outcomes included changes in noninvasive fibrosis indices: NAFLD Fibrosis Score (NFS), fibrosis-4 (FIB-4), and hepatic steatosis index (HSI). Secondary outcomes included liver enzymes, weight loss metrics, and glycemic parameters. RESULTS: Six studies comprising 220 patients (mean age 45 years; 67.5% female; mean baseline body mass index 38.9 kg/m²) with follow-up ranging from 6 to 12 months. EGR was associated with significant improvements in liver fibrosis indices, including NFS (mean difference - 0.65; 95% CI - 0.89 to - 0.42), FIB-4 (mean difference - 0.07; 95% CI - 0.22 to 0.07), and HSI (reduced from 50.36 ± 3.00 to 42.66 ± 2.38). Reductions in liver enzymes were observed, with pooled decreases of 14.39 U/L in alanine aminotransferase and 6.58 U/L in aspartate aminotransferase. EGR resulted in weight loss, with a pooled percent excess weight loss of 47.80% and a percent total weight loss of 16.24%. Glycemic control improved, with a 0.33% reduction in hemoglobin A1c and a 62% decrease in insulin resistance. No significant publication bias was detected (Begg-Mazumdar Kendall's tau b - 0.20, p = 0.48). CONCLUSIONS: Endoscopic gastric remodeling is a safe and effective minimally invasive therapy for MASLD. Further long-term studies are warranted to confirm the durability of these benefits.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.